IL-17 and IL-23 inhibitors are the most effective biologic therapies for achieving near-complete skin clearance in moderate to severe plaque psoriasis.
2
A Cochrane meta-analysis of 160 trials showed all systemic therapies outperformed placebo in achieving at least 90% improvement in PASI.
3
IL-17 inhibitors ranked highest in efficacy, followed by IL-23, IL-12/23, and TNF inhibitors, with small differences in individual drug effectiveness.
4
Serious adverse events were rare and similar across treatments, indicating a favorable safety profile for biologic therapies.
5
Oral therapies showed lower PASI 90 response rates compared to biologics but remain options for patients preferring oral treatment.
